Synchron, a major competitor to Neuralink, has secured a massive $305 million Series D round, catapu...
The AMW Read
This is an incremental funding update for a known player in the BCI/neurotech sub-sector, but it does not trigger cross.§D as the $305M round is below the $500M threshold.
Synchron, a major competitor to Neuralink, has secured a massive $305 million Series D round, catapulting the Brain-Computer Interface (BCI) sector forward. This substantial funding, which includes a $54 million investment from Australia's NRF, will accelerate the commercialization of its Stentrode BCI, a device unique for its minimally invasive, no open-brain surgery approach. The capital injection is a strong validation of Synchron's patient-first strategy, having already implanted the device in 10 patients to enable control of external devices like iPads and Vision Pro via thought. This significant funding signals that the race for BCI dominance is intensifying, with market readiness and regulatory progress now key differentiators from rivals.
